Krónikus limfoid leukémia (CLL): ki dolgozik rajta

Intézményenként egy kártya. Célpontra vagy országra szűkítheted a listát.

• Minden célpont
• BTK 26
• CD19 33
• BCL-2 10
• TP53 3
• CD20 10
• CD22 6
• ABL1 2
• PI3K 1
• NOTCH1 0
• CXCR4 0
• STAT3 0
• CD123 1
• CD38 1
• HMGB1 0
• PD-1 0
• PD-L1 0
• EGFR 0
• HDAC 0
• MDM2 0
• PPAR 0
• TIM-3 0
• AKT 0
• ALK 0
• ATM 0
• BCMA 1
• BDNF 0
• BRAF 0
• BRD4 0
• CD30 0
• CD47 0
• CSF1R 1
• CTNNB1 0
• ERK 0
• FAK 0
• FLT3 0
• IDH 0
• IL-23 0
• IL-4 0
• KMT2A 0
• MAPK 0
• MMP-9 0
• NLRP3 0
• NRAS 0
• PCSK9 0
• PRMT5 0
• TLR4 0
• VEGF 0

27+ intézményből 24, a friss publikációk és a nyitott vizsgálatok szerint rendezve. Ez nem minőségi rangsor.

Funded research projects that name this disease in their title, terms or summary and have not ended yet: who is funded, where, how much and until when. Organisations only; the funder's page has the details.

• NIH NCI · R01

  Overcoming ovarian cancer chemoresistance by co-targeting senescence and apoptosis

  Harvard University D/B/A Harvard School of Public Health· Boston, Egyesült Államok· 390 447 USD awarded in fiscal year 2026· until 2031. aug.

• NIH NCI · R01

  Rationally directed therapy for CLL

  University of Tx Md Anderson Can Ctr· Houston, Egyesült Államok· 690 011 USD awarded in fiscal year 2026· until 2031. aug.

• NIH NCI · R01

  Integrating AI and Deep Mutational Scanning to Predict the Cancer-Promoting Effect of Shelterin Mutations

  University of California Berkeley· Berkeley, Egyesült Államok· 2 197 943 USD awarded in fiscal year 2026· until 2029. aug.

• NIH NCI · R41

  Development of MCL 1-Targeting Antibody–Drug Conjugates for Cancer Therapy

  Immunogenic Cancer Engineering Therapeutics Llc· Englewood Cliffs, Egyesült Államok· 412 351 USD awarded in fiscal year 2026· until 2027. aug.

• NIH NEI · R01

  Discovery of novel trifunctional hybrid compounds (TFHCs): potential glaucoma therapy with superior IOP reduction and neuroprotection

  Creighton University· Omaha, Egyesült Államok· 576 730 USD awarded in fiscal year 2026· until 2031. júl.

• European Commission (Horizon Europe) · HORIZON-ERC

  Signaling and Powering Anti-cancer Responses in T Cells SPARC

  Stichting Amsterdam Umc· Amsterdam, Hollandia· EU contribution 2 500 000 EUR· until 2031. okt.

  The disease is named only in the funder's project summary, not in the title.

• European Commission (Horizon Europe) · HORIZON-ERC-POC

  SMART-SMAPs: a new paradigm of cell-free cytotoxic immunotherapy for resistant CLL

  Universita Degli Studi di Siena· Siena, Olaszország· EU contribution 150 000 EUR· until 2028. márc.· 2 countries

• European Commission (Horizon Europe) · HORIZON-ERC-POC

  Immuno-Modulatory Platform for Advanced CLL Therapy (IMPACT)

  Stichting Amsterdam Umc· Amsterdam, Hollandia· EU contribution 150 000 EUR· until 2028. márc.

• European Commission (Horizon Europe) · HORIZON-ERC-POC

  Targeting GAB1: a novel therapeutic strategy for the treatment of leukemias (LeukemiaBlock)

  Masarykova univerzita· Brno, Csehország· EU contribution 150 000 EUR· until 2028. febr.

  The disease is named only in the funder's project summary, not in the title.

• European Commission (Horizon Europe) · HORIZON-ERC-POC

  A single-cell-based solution for an early diagnosis of Richter transformation in patients with chronic lymphocytic leukemia (earlyRTdx)

  Fundacio de Recerca Clinic Barcelona-Institut D Investigacions Biomediques August Pi I Sunyer· Barcelona, Spanyolország· EU contribution 150 000 EUR· until 2027. okt.

10 of 143 running projects, newest first. Listed amounts together: 97,4 M USD + 16,8 M EUR.

Sources: NIH RePORTER (U.S. National Institutes of Health, public domain) and CORDIS (European Commission, CC BY 4.0). Changes: filtered by disease, organisations matched to ROR.

Leállított, visszavont és felfüggesztett vizsgálatok, a szponzor által a regiszterben megadott okkal, szó szerint idézve.

• Visszavonták

  Anti-CD19 CAR-Engineered NK Cells in the Treatment of Relapsed/Refractory B-cell Malignancies

  NCT05410041· Beijing Boren Hospital· Frissítve: 2026. okt. 15.

  “No participants.”A regiszter szövege, változtatás nélkül. Forrás

• Felfüggesztve

  Universal CAR-T Cells (REVO-UWD-19) for Refractory and Relapsed B-Cell Tumors

  NCT06662227· Wondercel Biotech (ShenZhen)· Frissítve: 2026. máj. 7.

  “Because the implementation of the new regulation policy by the Chinese authority”A regiszter szövege, változtatás nélkül. Forrás

• Leállították

  A Study Evaluating Safety, PK, and Efficacy of Tafasitamab and Parsaclisib in Participants With Relapsed/Refractory Non Hodgkin Lymphoma (R/R NHL) or Chronic Lymphocytic Leukemia (CLL)

  NCT04809467· Incyte Corporation· Frissítve: 2026. febr. 4.

  “A business decision was made to discontinue further enrollment. There were no safety concerns that contributed to this decision.”A regiszter szövege, változtatás nélkül. Forrás

• Leállították

  Genetically Engineered Cells (EGFRt/19-28z/IL-12 CAR T Cells) for the Treatment of Relapsed or Refractory CD19+ Hematologic Malignancies

  NCT06343376· Roswell Park Cancer Institute· Frissítve: 2025. aug. 3.

  “Manufacturing issues”A regiszter szövege, változtatás nélkül. Forrás

• Leállították

  CAR20.19.22 T-cells in Relapsed, Refractory B-cell Malignancies

  NCT05094206· Medical College of Wisconsin· Frissítve: 2024. szept. 19.

  “Treated four patients: 2 at a dose of 1x10\^6 cells/kg and 2 ad at dose of 2.5x10\^6 cells/kg. All four patients had no in-vivo expansion and no meaningful response to therapy. At this point per FDA guidance we will not be treating more patients.”A regiszter szövege, változtatás nélkül. Forrás

• Visszavonták

  A Study to Compare the Efficacy and Safety of Lisocabtagene Maraleucel vs Investigator's Choice Options in Adult Participants With Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma, Whose Disease Has Failed Treatment With Both BTKi and BCL2i Therapies

  NCT06205290· Juno Therapeutics, Inc., a Bristol-Myers Squibb Company· Frissítve: 2024. ápr. 2.

  “Business objectives have changed.”A regiszter szövege, változtatás nélkül. Forrás

• Visszavonták

  Interleukin-2 Following 4SCAR19/22 T Cells Targeting Refractory and/or Recurrent B Cell Malignancies

  NCT03098355· Zhujiang Hospital· Frissítve: 2024. márc. 18.

  “The company did not offer the appropriate CART services.”A regiszter szövege, változtatás nélkül. Forrás

• Visszavonták

  CD19 CAR T-cell Target Relapsed/Refractory Acute B Cell Leukemia/Lymphoma

  NCT05613348· Zhujiang Hospital· Frissítve: 2024. márc. 18.

  “The company failed to provide corresponding CART services.”A regiszter szövege, változtatás nélkül. Forrás

• Visszavonták

  Programmed Allogeneic CRISPR-edited T Cells Engineered to Express Anti-CD19 Chimeric Antigen Receptor (PACE CART19) in Patients With Relapsed Or Refractory CD19+ Leukemia and Lymphoma

  NCT05037669· University of Pennsylvania· Frissítve: 2023. jún. 22.

  “No available investigational product”A regiszter szövege, változtatás nélkül. Forrás

• Visszavonták

  Anti-CD19 Universal CAR-NK Cells Therapy Combined With HSCT for B Cell Hematologic Malignancies

  NCT05570188· Kunming Hope of Health Hospital· Frissítve: 2022. nov. 30.

  “The PI decides to stop.”A regiszter szövege, változtatás nélkül. Forrás

Vizsgálatok, amelyek regiszteradata szerint az egyéni résztvevői adatokat (IPD) megosztják.

• Administration of Anti-CD19-chimeric-antigen-receptor-transduced T Cells From the Original Transplant Donor to Patients With Recurrent or Persistent B-cell Malignancies After Allogeneic Stem Cell Transplantation

  NCT01087294· National Cancer Institute (NCI)· Forrás

• CD19/CD22 Bicistronic Chimeric Antigen Receptor (CAR) T Cells in Children and Young Adults With Recurrent or Refractory B Cell Malignancies

  NCT05442515· National Cancer Institute (NCI)· Forrás

• Anti-CD19 Chimeric Antigen Receptor T-Cell Immunotherapy for Leukemias

  NCT06364423· National Cancer Institute (NCI)· Forrás

• Trial of Anti-CD19 and Anti-CD20 Bicistronic Chimeric Antigen Receptor T Cells for Treating B-Cell Malignancies

  NCT05797233· National Cancer Institute (NCI)· Forrás

• Human AntiCD19 Chimeric Antigen Receptor T Cells for Relapsed or Refractory Lymphoid Malignancies

  NCT04732845· Benjamin Tomlinson· Forrás

• 19(T2)28z1xx Chimeric Antigen Receptor (CAR) T Cells in People With B-Cell Cancers

  NCT04464200· Memorial Sloan Kettering Cancer Center· Forrás

• A Study Evaluating Safety, PK, and Efficacy of Tafasitamab and Parsaclisib in Participants With Relapsed/Refractory Non Hodgkin Lymphoma (R/R NHL) or Chronic Lymphocytic Leukemia (CLL)

  NCT04809467· Incyte Corporation· Forrás

• CD19/CD22 Chimeric Antigen Receptor (CAR) T Cells in Children and Young Adults With Recurrent or Refractory CD19/CD22-expressing B Cell Malignancies

  NCT03448393· National Cancer Institute (NCI)· Forrás

• Intravenous Autologous CD19 CAR-T Cells for R/ R MM, B-ALL, and B-Cell Lymphoma

  NCT06961669· Anhui Provincial Hospital· Forrás

• CAR2219 CAR-T Cells for the Treatment of R/R B Cell Leukemia and Lymphoma

  NCT06834529· Affiliated Hospital to Academy of Military Medical Sciences· Forrás

Publikációk erről a betegségről egy MeSH-módszerkifejezés szerint, például szekvenálási vagy képalkotó módszerre.

• Single-Cell Analysis 6
• Mendelian Randomization Analysis 2
• CRISPR-Cas Systems 1
• Gene Expression Profiling 9
• Sequence Analysis, RNA 1
• Whole Genome Sequencing 1
• Exome Sequencing 1
• Proteomics 3
• Metabolomics 1
• Mass Spectrometry 2
• Flow Cytometry 21
• Immunohistochemistry 6
• Circulating Tumor DNA 1
• Xenograft Model Antitumor Assays 9
• Magnetic Resonance Imaging 4
• Machine Learning 10
• Cohort Studies 18
• Genome-Wide Association Study 2

• Multi-omics data integration in bioinformatics: methods, applications, and the path toward biological reasoning.

  Funct Integr Genomics, 2026. nov.

• Reduction-Free Thermolysin Digestion Enables Absolute Protein Quantitation in Plasma in 35 min from Sample to Result.

  J Proteome Res, 2026. máj.

• Proteomic and Functional Comparison of Extracellular Vesicles from Wild-Type and Lyn-Deficient Stromal Cells.

  Adv Exp Med Biol, 2026. jan.

Megmutatjuk, a betegség mely célpontjait említi az absztrakt, és onnan a rajtuk dolgozókhoz jutsz.